Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies

Journal of Immunological Methods

Volumn 339, Issue 1, 2008, Pages 55-65

  Rasch, Morten G ^a   Pass, Jesper ^b   Illemann, Martin ^a   Høyer Hansen, Gunilla ^a   Lund, Ida K ^a  

^a FINSEN LABORATORY   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Cleaved uPAR; Monoclonal antibodies; Surface plasmon resonance; uPA; uPAR; uPAR localisation

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MR1; MONOCLONAL ANTIBODY MR3; MONOCLONAL ANTIBODY MR4; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING SITES, ANTIBODY; CELL LINE; CELL MEMBRANE; HUMANS; MICE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SURFACE PLASMON RESONANCE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

MURINAE;

EID: 54849392100     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.08.002     Document Type: Article

References (44)

1. Behrendt N., Rønne E., and Danø K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J. Biol. Chem. 271 (1996) 22885
2. Bernstein A.M., Twining S.S., Warejcka D.J., Tall E., and Masur S.K. Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol. Biol. Cell 18 (2007) 2716
3. Blasi F., and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev., Mol. Cell Biol. 3 (2002) 932
4. Czekay R.P., Kuemmel T.A., Orlando R.A., and Farquhar M.G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12 (2001) 1467
5. Danø K., Nielsen L.S., Møller V., and Engelhart M. Inhibition of a plasminogen activator from oncogenic virus-transformed mouse cells by rabbit antibodies against the enzyme. Biochim. Biophys. Acta 630 (1980) 146
6. Danø K., Behrendt N., Høyer-Hansen G., Johnsen M., Lund L.R., Ploug M., and Rømer J. Plasminogen activation and cancer. Thromb. Haemost. 93 (2005) 676
7. de StGroth S.F., and Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35 (1980) 1
8. Dickinson, M.E., Bearman, G., Tille, S., Lansford, R. and Fraser, S.E., 2001. Multi-spectral imaging and linear unmixing add a whole new dimension to laser scanning fluorescence microscopy. Biotechniques 31, 1272, 1274, 1278.
9. Gårdsvoll H., Solberg H., Danø K., and Høyer-Hansen G. Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization. J. Immunol. Methods 234 (2000) 107
10. Gårdsvoll H., Werner F., Søndergaard L., Danø K., and Ploug M. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. Protein Expr. Purif. 34 (2004) 284
11. Gårdsvoll H., Gilquin B., Le Du M.H., Menez A., Jørgensen T.J., and Ploug M. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J. Biol. Chem. 281 (2006) 19260
12. Gårdsvoll H., and Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem. 282 (2007) 13561
13. Green K.A., and Lund L.R. ECM degrading proteases and tissue remodelling in the mammary gland. BioEssays 27 (2005) 894
14. Hedberg K.K., Stauff C., Høyer-Hansen G., Rønne E., and Griffith O.H. High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Exp. Cell Res. 257 (2000) 67
15. Heegaard C.W., Simonsen A.C., Oka K., Kjøller L., Christensen A., Madsen B., Ellgaard L., Chan L., and Andreasen P.A. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J. Biol. Chem. 270 (1995) 20855
16. Høyer-Hansen G., Rønne E., Solberg H., Behrendt N., Ploug M., Lund L.R., Ellis V., and Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267 (1992) 18224
17. Høyer-Hansen G., Behrendt N., Ploug M., Danø K., and Preissner K.T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420 (1997) 79
18. Høyer-Hansen G., and Lund I.K. Urokinase receptor variants in tissue and body fluids. Adv. Clin. Chem. 44 (2007) 65
19. Huai Q., Mazar A.P., Kuo A., Parry G.C., Shaw D.E., Callahan J., Li Y., Yuan C., Bian C., Chen L., Furie B., Furie B.C., Cines D.B., and Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science 311 (2006) 656
20. List K., Høyer-Hansen G., Rønne E., Danø K., and Behrendt N. Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J. Immunol. Methods 222 (1999) 125
21. Lund L.R., Green K.A., Stoop A.A., Ploug M., Almholt K., Lilla J., Nielsen B.S., Christensen I.J., Craik C.S., Werb Z., Danø K., and Rømer J. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J. 25 (2006) 2686
22. Luther T., Magdolen V., Albrecht S., Kasper M., Riemer C., Kessler H., Graeff H., Muller M., and Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol. 150 (1997) 1231
23. Mahanivong C., Yu J., and Huang S. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. Mol. Carcinog. 46 (2007) 165
24. Myohanen H.T., Stephens R.W., Hedman K., Tapiovaara H., Rønne E., Høyer-Hansen G., Danø K., and Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 41 (1993) 1291
25. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 52 (1992) 6754
26. Pass J., Jögi A., Lund I.K., Rønø B., Rasch M.G., Gårdsvoll H., Lund L.R., Ploug M., Rømer J., Danø K., and Høyer-Hansen G. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb. Haemost. 97 (2007) 1013
27. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des 9 (2003) 1499
28. Ploug M., Ellis V., and Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 33 (1994) 8991
29. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., and Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138 (1991) 1059
30. Pyke C., Graem N., Ralfkiaer E., Rønne E., Høyer-Hansen G., Brünner N., and Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 53 (1993) 1911
31. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., and Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15 (1996) 1572
32. Rømer J., Pyke C., Lund L.R., Eriksen J., Kristensen P., Rønne E., Høyer-Hansen G., Danø K., and Brünner N. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int. J. Cancer 57 (1994) 553
33. Rønne E., Behrendt N., Ellis V., Ploug M., Danø K., and Høyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett. 288 (1991) 233
34. Rønne E., Høyer-Hansen G., Brünner N., Pedersen H., Rank F., Osborne C.K., Clark G.M., Danø K., and Grøndahl-Hansen J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res. Treat. 33 (1995) 199
35. Rømer J., Pyke C., Lund L.R., Ralfkiaer E., and Danø K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J. Invest Dermatol. 116 (2001) 353
36. Shulman M., Wilde C.D., and Kohler G. A better cell line for making hybridomas secreting specific antibodies. Nature 276 (1978) 269
37. Solberg H., Løber D., Eriksen J., Ploug M., Rønne E., Behrendt N., Danø K., and Høyer-Hansen G. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur. J. Biochem. 205 (1992) 451
38. Solberg H., Rømer J., Brünner N., Holm A., Sidenius N., Danø K., and Høyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer 58 (1994) 877
39. Stoppelli M.P., Tacchetti C., Cubellis M.V., Corti A., Hearing V.J., Cassani G., Appella E., and Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45 (1986) 675
40. Usher P.A., Thomsen O.F., Iversen P., Johnsen M., Brünner N., Høyer-Hansen G., Andreasen P., Danø K., and Nielsen B.S. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int. J. Cancer 113 (2005) 870
41. Vassalli J.D., Baccino D., and Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100 (1985) 86
42. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., and Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269 (1994) 32380
43. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., and Chapman H.A. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 12 (2001) 2975
44. Yuan C., and Huang M. Does the urokinase receptor exist in a latent form?. Cell. Mol. Life Sci. 64 (2007) 1033